Boehringer Ingelheim
Family-owned German pharma and the largest private GLP-1 challenger, anchored by survodutide for obesity and MASH
Ingelheim am Rhein, Germany~54,500 (group)Founded 1885Privately held (not publicly traded) raisedwww.boehringer-ingelheim.com
SectorsGLP-1
Market Metrics
Net Sales (2024)
€26.8B
+6% (currency-adjusted)
Human Pharma Sales (2024)
€21.9B
Animal Health Sales (2024)
€4.7B
R&D Investment (2024)
€6.2B
23.2% of net sales
Employees
~54,500
Ownership
100% family-owned
Lead GLP-1 Asset
Survodutide (Ph3)
16.6% weight loss (SYNCHRONIZE-1)
Updated at 2024-FY
Funding History
Total raised: Privately held (not publicly traded)
| Round | Date | Amount | Valuation | Key Investors |
|---|
Updated at 2024-FY
Product Specifications
| Asset | Mechanism | Stage | Indications | Notes |
|---|---|---|---|---|
| Survodutide (BI 456906) | GLP-1 / glucagon dual agonist | Phase 3 | Obesity, MASH | Lead metabolic asset, licensed from and co-developed with Zealand Pharma. SYNCHRONIZE-1 reported 16.6% mean weight loss at 76 weeks (Apr 2026). LIVERAGE (MASH) program ongoing |
| Jardiance (empagliflozin) | SGLT2 inhibitor | Marketed | Type 2 diabetes, heart failure, CKD | Flagship cardio-renal-metabolic franchise, marketed in alliance with Eli Lilly |
| Ofev (nintedanib) | Tyrosine kinase inhibitor | Marketed | Idiopathic pulmonary fibrosis, ILD | Leading anti-fibrotic franchise |
Updated at 2026-Q2
Partnerships & Investors
Zealand PharmaLicensing / Co-Development
Survodutide originated from Zealand Pharma; Boehringer leads global development and commercialization, with milestone and royalty payments to Zealand
Eli LillyStrategic Alliance
Diabetes alliance (since 2011) underpinning the Jardiance franchise
Updated at 2026-Q2
Key Milestones
1885
Company Founded
Albert Boehringer establishes the business in Ingelheim am Rhein, Germany
2011
Diabetes Alliance with Eli Lilly
Forms a diabetes alliance with Eli Lilly that later produces Jardiance (empagliflozin), a flagship cardio-renal-metabolic product
Sep 2024
Survodutide Breakthrough Therapy (MASH)
Survodutide (GLP-1/glucagon dual agonist) receives FDA Breakthrough Therapy designation for non-cirrhotic MASH with moderate-to-advanced fibrosis
2024
Phase 3 Program Underway
Advances survodutide into Phase 3: SYNCHRONIZE for obesity and overweight, LIVERAGE for MASH
Apr 2026
SYNCHRONIZE-1 Obesity Results
Survodutide delivers 16.6% mean weight loss at 76 weeks versus 3.2% on placebo (p<0.0001); 85.1% of treated adults lost at least 5% of body weight
Updated at 2026-Q2